Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02035345 · ClinicalTrials.gov registry record · Phase 4

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

A Phase 4 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 4
Development phase
15
Enrollment target

NCT02035345: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.

NCT02035345 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02035345, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 4
Development phase
15 participants
Enrollment target

Study Summary

This is a research study to determine if administering carboplatin at a slower rate when re-treating recurrent ovarian cancer patients prior to the development of a hypersensitivity reaction will decrease the frequency and severity of future hypersensitivity reactions.

Primary Outcome

To determine the frequency of carboplatin infusion hypersensitivity reactions using a slowed carboplatin infusion program

Interventions

  • DRUG Carboplatin

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2014-01
Est. Completion 2016-06
Phase Phase 4
Massachusetts General Hospital

2,032 total trials

Why NCT02035345 stopped before completion

NCT02035345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Carboplatin is the first listed.

NCT02035345 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02035345 about?

NCT02035345 is a clinical study titled "Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment". This is a research study to determine if administering carboplatin at a slower rate when re-treating recurrent ovarian cancer patients prior to the development of a hypersensitivity reaction will decrease the frequency and severity of future hypersensitivity reactions.

What is the current status of trial NCT02035345?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2014-01. Estimated completion is 2016-06.

What interventions are being tested in trial NCT02035345?

The interventions under investigation include: Carboplatin (DRUG).

Who is sponsoring clinical trial NCT02035345?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02035345's enrollment target sits among peer trials

15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02035345, the US trial registry maintained by the National Library of Medicine. NCT02035345 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.